CoChat

The DOI matches its Crossref record; 23 of the 25 references it cites were found in a registry or an index.

Copayment mechanism in selected districts of Uganda: Availability, market share and price of quality assured artemisinin-based combination therapies in private drug outlets

Open access
Ocan, Moses, Nambatya, Winnie, Otike, Caroline, Nakalembe, Loyce, Nsobya, Sam · 2024 · PLOS ONE

Abstract

Background: Malaria remains one of the leading causes of morbidity, and mortality in Uganda. A large proportion of malaria symptomatic patients seek healthcare in private sector. However, availability and affordability are major barriers to access to effective treatment. The private sector copayment mechanism in Uganda aims to increase availability and affordability of antimalarial agents. Our study assessed availability, price, and market share of quality assured artemisinin-based combination therapies (QAACTs) in private drug outlets in selected districts during the implementation of copayment mechanism. Methods: This was a cross-sectional survey of anti-malarial agents in private drug outlets in in selected moderate-to-high (Tororo, and Apac districts) and low (Kabale and Mbarara districts) malaria transmission settings. Following the World Health Organization/Health Action International (WHO/HAI) criteria, an audit of the antimalarial agents was done using a checklist to determine availability, price, and market share of QAACTs. Data were entered in Epi-data and analyzed in STATA ver 14.0 at 95% confidence level. Results: A total of twenty-eight (28) private drug outlets (pharmacies and drug shops) were included in the survey. One in seven (20/144: 95%CI: 9.1, 20.6) of the antimalarial agents in private drug outlets were quality assured artemisinin-based combination therapies (QAACT). Artemether-lumefantrine (AL), 8.9% (11/124) and Artesunate-Amodiaquine (AQ), 7.3% (9/124) were the only QAACTs present in the drug outlets at the time of the survey. The majority, 86.1%% (124/144) of antimalarial agents present in stock in the drug outlets were artemisinin based. The most common, 38.9% (56/144) ACT in the drug outlets was Dihydroartemisinin-Piperaquine (DHP). Most, 69.4% (100/144) of the antimalarial agents were in high malaria transmission settings. The cost of ACT antimalarial agents is high in the country, USD 1.4 (Artemether-Lumefantrine, AL), USD 2.4 (Dihydroartemisinin-Piperaquine, DP), the first line and second-line agents respectively for treatment of uncomplicated malaria in Uganda. There was a statistically significant difference between the dispensing price of ‘Green leaf’ ACTs (QAACT) and the recommended price (p<0.001). Predictors of availability of QAACT in private drug outlets include pharmacy drug outlet (aPR:0.4; 95%CI: 0.2, 0.9) and dispensing price more than 3000UGX (USD 0.83) (aPR: 0.4, 95%CI: 0.1, 0.51). Conclusion: Quality assured artemisinin-based combination therapies (QAACTs) are not common in private drug outlets in selected districts in Uganda. All the drug outlets had at least one ACT antimalarial agent present on the day of the survey. The dispensing price of QAACTs was significantly higher than the recommended markup price. There is need for awareness creation, surveillance, and monitoring of the implementation of Copayment mechanism in the country.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0295198

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Research works printed but not linked: 11

  1. World Health Organisation, 2022, World malaria report 2022.
  2. 2023, Ministry of Health. Malaria quarterly report.
  3. Uganda Bureau of Statistics (UBOS) and ICF, 2018, Uganda Demographic and Health Survey 2016.
  4. UBOS, 2017, Uganda national household survey 2016/17.
  5. World Health Organisation., 2008, Medicines strategy 2008–2013.
  6. Roll Back Malaria, 2011, Updated ACT prices under the Affordable Medicines Facility-malaria 1 March 2011 fact sheet.
  7. HEPS-Uganda, 2017, Assessing Access to Co-Paid Artemisinin-Based Combination Therapies for Malaria in Uganda.
  8. Ministry of Health, 2014, The Uganda Malaria Reduction Strategic Plan (2014–2020): accelerated nationwide scale up to achieve universal coverage of cost effective malaria prevention and treatment interventions.
  9. World Health Organization/Health Action International., 2003, Medicine prices: a new approach to measurement.
  10. Ministry of Health, 2011, Uganda National Malaria Control Policy.
  11. World Health Organization, 2015, Guidelines for the treatment of malaria

Cited by

See all 1

Metadata

Authors
Ocan, M., Nambatya, W., Otike, C., Nakalembe, L., & Nsobya, S.
Affiliations
  • Makerere University (UG)
  • Joint Clinical Research Centre (UG)
  • Soroti University (UG)
Corresponding author
Ocan, Moses
Venue
PLOS ONE
Published
2024-03-27
Volume
19
Issue
3
Pages
e0295198
ISSN
1932-6203 (ISSN-L)
OpenAlex
W4393235030
Cited by
1
References
25
Citations by year
2024: 1
FWCI
0.35
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Greater South Information System
Funders
EDCTP2 (TMA2019CDF-2662 (Pfkelch13 emergence))
Topics
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pharmaceutical Quality and Counterfeiting
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
Keywords
artemisinin-based combination therapy, antimalarial drug availability, drug pricing, market share, malaria treatment access, artemether-lumefantrine, dihydroartemisinin-piperaquine, artemisinin resistance, quality assurance
MeSH terms
Artemether, Artemether, Lumefantrine Drug Combination, Antimalarials, Cross-Sectional Studies, Humans, Malaria, Uganda, Artemisinins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Copayment mechanism in selected districts of Uganda: Availability, market share and price of quality assured artemisinin-based combination therapies in private drug outlets. https://app.cochat.ai/papers/10.1371/journal.pone.0295198
The paper
Ocan, M., Nambatya, W., Otike, C., Nakalembe, L., & Nsobya, S. (2024). Copayment mechanism in selected districts of Uganda: Availability, market share and price of quality assured artemisinin-based combination therapies in private drug outlets. PLOS ONE. https://doi.org/10.1371/journal.pone.0295198

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.